Chimeric Therapeutics Ltd has released a press release.
Chimeric licenses novel solid tumor CAR T therapy from Penn
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial
- Appendix 4C - quarterly
- Successful Completion of First Patient Cohort Phase 1 Trial
- Successful Completion of Dosing in First Patient Cohort
Later from Chimeric Therapeutics
- IND clearance received from US FDA for CHM 1101
- Chimeric Appoints Jennifer Chow as CEO & MD
- Preliminary Final Report
- Partnership with OncoBay Clinical to advance CHM 1101
- European patent granted for CLTX technology used in CHM 1101
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics